EyePoint Pharmaceuticals (EYPT)
(Delayed Data from NSDQ)
$17.50 USD
-3.44 (-16.43%)
Updated Apr 18, 2024 04:00 PM ET
After-Market: $17.49 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
EyePoint Pharmaceuticals (EYPT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$41.50 | $55.00 | $33.00 | 137.14% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for EyePoint Pharmaceuticals comes to $41.50. The forecasts range from a low of $33.00 to a high of $55.00. The average price target represents an increase of 137.14% from the last closing price of $17.50.
Analyst Price Targets (8 )
Broker Rating
EyePoint Pharmaceuticals currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on nine recommendations.
Of the nine recommendations deriving the current ABR, nine are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 9 | 9 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/8/2024 | H.C. Wainwright & Co. | Yi Chen | Strong Buy | Strong Buy |
2/16/2024 | Chardan Capital Markets | Daniil Gataulin | Strong Buy | Strong Buy |
2/16/2024 | Capital One Securities | Timothy Chiang | Not Available | Strong Buy |
2/1/2024 | Robert W. Baird & Co. | Colleen M Kusy | Strong Buy | Strong Buy |
12/7/2023 | Mizuho SecuritiesUSA | Graig Suvannavejh | Strong Buy | Strong Buy |
12/4/2023 | Guggenheim Securities | Yatin Suneja | Strong Buy | Strong Buy |
11/2/2023 | Cantor Fitzgerald & Co | Jennifer Kim | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 9 |
Average Target Price | $41.50 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 84 of 252 |
Current Quarter EPS Est: | -0.34 |